Exciting news for the CLOVES/PROS community: FDA approves Novartis Vijoice (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

  • Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1.
  • PROS is a spectrum of rare conditions and is characterized by atypical overgrowths and anomalies in blood vessels, the lymphatic system and other tissues.
  • Approval based on real-world data from EPIK-P1 study, which showed patients treated with Vijoice experienced reduction in the size of PROS lesions and improvement of PROS-related signs and symptoms
  • Novartis to offer robust patient support program that includes assistance to access medication, financial resources for eligible patients and continued education

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9015251-fda-approves-novartis-vijoice-as-treatment-for-pros